Literature DB >> 18622285

Liver transplantation trends for older recipients: regional and ethnic variations.

Nyingi Kemmer1, Kamran Safdar, Tiffany E Kaiser, Victoria Zacharias, Guy W Neff.   

Abstract

BACKGROUND: Liver transplantation (LT) provides long-term survival for adults with end-stage liver disease. As a result of improved survival and an aging United States population the demand for LT in older patients is expected to increase. The aim of this study was to describe the transplantation trends in the older recipient (older than 65 years).
METHODS: Using the United Network for Organ Sharing database, we identified LT recipients between 1990 and 2006. We used Kaplan-Meier method to calculate overall survival (1, 3, 5 and 10 years) and Cox regression for predictors of survival.
RESULTS: During the study period 5630 (7.6%) LT recipients were older than 65 years. There were 4256 (79.4%) whites, Hispanic (10.3%), African Americans (AA) (3.6%), and rest (6.7%). There was an increase in LT for older than 65 years from 4.1% in 1990 to 10.2% in 2006 (P=0.002) and a regional variation (P<0.001). The 10-year patient and graft survival was 60% and 57% for less than 65 years versus 42% and 40% for more than 65 years (P<0.0001). With age stratification (65-75 years vs. >75 years), there was no difference in survival but when adjusted for race there was a significant difference in graft survival with a 10 year (white 40%, Hispanic 44%, and AA 19%) (P=0.04).
CONCLUSION: The demand for LT in recipients older than 65 years is increasing. Although their survival is lower in comparison with recipients less than 65 years, there seems to be no difference in unadjusted survival with age stratification above 65 years. Among ethnic minorities, there was a disproportionately lower percentage of African Americans LT and a decreased survival.

Entities:  

Mesh:

Year:  2008        PMID: 18622285     DOI: 10.1097/TP.0b013e318176b4c1

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  De novo malignancy post-liver transplantation: a single center, population controlled study.

Authors:  Hemant Chatrath; Kenneth Berman; Raj Vuppalanchi; James Slaven; Paul Kwo; A Joseph Tector; Naga Chalasani; Marwan Ghabril
Journal:  Clin Transplant       Date:  2013-06-30       Impact factor: 2.863

2.  Outcomes among older adult liver transplantation recipients in the model of end stage liver disease (MELD) era.

Authors:  Maricar F Malinis; Shu Chen; Heather G Allore; Vincent J Quagliarello
Journal:  Ann Transplant       Date:  2014-09-26       Impact factor: 1.530

3.  Ethnic and Age Disparities in Outcomes Among Liver Transplant Waitlist Candidates.

Authors:  Margaux N Mustian; Brittany A Shelton; Paul A MacLennan; Rhiannon D Reed; Jared A White; Devin E Eckhoff; Jayme E Locke; Richard M Allman; Stephen H Gray
Journal:  Transplantation       Date:  2019-07       Impact factor: 4.939

4.  The augmenter of liver regeneration protects the kidneys after orthotopic liver transplantation possibly by upregulating HIF-1α and O2-sensitive K+ channels.

Authors:  Yao Chen; Fang Luo; Shiqiao Luo; Zhongjun Wu; Jian Zhou
Journal:  Surg Today       Date:  2011-03-02       Impact factor: 2.549

5.  Liver transplantation trends in the HIV population.

Authors:  Nyingi M Kemmer; Kenneth E Sherman
Journal:  Dig Dis Sci       Date:  2011-08-30       Impact factor: 3.199

Review 6.  Transplant of Elderly Patients: Is There an Upper Age Cutoff?

Authors:  Claudia Cottone; Nathalie A Pena Polanco; Kalyan Ram Bhamidimarri
Journal:  Clin Liver Dis       Date:  2020-10-21       Impact factor: 6.126

7.  Who does the model learn from?

Authors:  Marie-Laure Charpignon; Leo Anthony Celi; Mathew Cherian Samuel
Journal:  Lancet Digit Health       Date:  2021-04-12

8.  Outcomes Between Elderly and Young Hepatocellular Carcinoma Living Donor Liver Transplantation Recipients: A Single-Center Experience.

Authors:  Hong Yu Li; Yong Gang Wei; Lv Nan Yan; Bo Li
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.